Evidence map›Paper›PMID 21103946›Full record

ReviewJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2011

Neuroimmune pharmacology as a sub-discipline of medical neuroscience in the medical school curriculum.

Robert W Freilich, Tsuneya Ikezu

Abstract readReview
In one paragraph

Review in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Education Mission for Neuroimmune PharmacologyJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Robert W FreilichDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA. robf999@bu.edu
Tsuneya Ikezu

Funding

TRAINING IN BIOMOLECULAR PHARMACOLOGYT32GM008541 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FARB, DAVID H · 1997 to 2022
$5.2M
OTK18 Regulation in HIV-1 associated dementiaR01MH072539 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI IKEZU, TSUNEYA · 2005 to 2009
$1.2M
Anti-inflammatory regulation of beta-amyloidosisR21AG032600 · NIA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI IKEZU, TSUNEYA · 2009 to 2010
$346k
NIA NIH HHS R21 AG032600NIGMS NIH HHS 5T32GM008541NIGMS NIH HHS T32 GM008541NIMH NIH HHS R01 MH072539
6 · The paper itself

Abstract

The emerging field of neuroimmune pharmacology (NIP) is the confluence of three distinct disciplines: neuroscience, immunology, and pharmacology (Gendelman and Ikezu 2008). NIP was born from the realization that inflammation within the central nervous system (CNS) plays a crucial role in many neurological pathologies and as such offers a rich array of novel pharmacological targets as potential therapeutics. As this field is likely to have a major impact in medical science, educating future physicians on this area will help increase awareness and may potentially inspire them to pursue careers in the field of NIP. However, a key challenge for medical educators, is how best to incorporate new material on emerging fields, such as NIP, into the medical school curriculum, specifically in the context of a medical neuroscience course. We propose the addition of two 50-min lectures plus an additional optional 2-h lab module to the standard first year medical neuroscience class curriculum. Lecture 1 will focus on how the CNS and the immune system inter-communicate with one another with emphasis on neuroanatomical features and chemical signal transduction between the two systems. Lecture 2 provides an introduction to inflammation in the CNS and provides a series of clinical correlates to describe how CNS inflammation contributes to the disease process. The lab module provides detailed visual examples of how CNS inflammation influences disease processes and provides two examples of how application of an immunomodulatory pharmacological agent can modify disease processes.

Indexed as

Allergy and ImmunologyEducation, Medical, UndergraduateHumansNeurosciencesPharmacology

Identifiers

PMID21103946
PMCPMC3101078

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.